Interestingly, while there are no statistically significant differences in APRIL levels in either serum or CSF among the four groups of subjects stratified based on LRRK2 mutation and PD status, reduced CSF: serum ratio of APRIL was significantly associated with both LRRK2 mutations and PD. The gene discussed is TNFSF13; the disease is Parkinson disease.